PharmacoEconomics and Outcomes News

AD health utilities: reflecting on the recent UK NICE decision
pp. 2-2(1)

Pimecrolimus itching to prove its worth in atopic dermatitis
pp. 3-4(2)

Substantial delays in US infant vaccinations: better late than never?
pp. 4-4(1)

The pros and cons of Rx-to-OTC switching of drugs in the US
pp. 5-5(1)

UK hep A, B vaccination guidance for injection drug users issued
pp. 5-5(1)

Countries need help making decisions about Hib vaccination
pp. 5-5(1)

Expert panel discusses Vioxx alternatives
pp. 5-5(1)

Carmellose leg ulcer dressing best value in Germany and the US
pp. 6-6(1)

PEP should be better targeted in France to enhance cost effectiveness
pp. 6-6(1)

Aspirin adherence wanes in patients with depression
pp. 6-6(1)

Lifestyle modification best option for preventing type 2 DM
pp. 7-7(1)

CBT "feasible alternative" to antidepressants in the UK
pp. 7-7(1)

Short-term transdermal fentanyl use common in The Netherlands
pp. 7-7(1)

Sivelestat cost saving for acute lung injury in Japan
pp. 9-9(1)

Routine pneumococcal vaccination reasonably cost effective in Spain
pp. 9-9(1)

Neural tube defect rate unchanged despite folic acid supplementation
pp. 9-9(1)

Staphylococcus aureus poststernotomy mediastinitis following sternotomy for cardiac surgery is associated with substantial costs in New Zealand
pp. 10-10(1)

Concern, confusion over COX-2s leads to reduction in use
pp. 10-10(1)

Herd immunity confers added cost benefit for pneumococcal vax
pp. 10-10(1)

Switch from IV to oral quinolones cost saving for Spanish hospital
pp. 10-10(1)

Off-label antipsychotic use common among US elderly, disabled
pp. 11-11(1)

Screening every 3 years "optimal" for type 2 diabetes mellitus
pp. 11-11(1)

HRT underused by menopausal women despite need for treatment
pp. 11-11(1)

Amantadine "consistently cost saving" among healthy US workers
pp. 12-12(1)

Celecoxib most cost-effective choice in high-risk arthritis patients
pp. 12-12(1)

Immunisation guideline compliance low, errors common among infants
pp. 13-13(1)

Childhood asthma common and costly in the EU
pp. 13-13(1)

Rosuvastatin STELLAR option for lowering LDL-cholesterol
pp. 13-13(1)

Medical resident compliance with NCEP ATP III "suboptimal"
pp. 14-14(1)

Clopidogrel worthwhile secondary prevention for vascular events
pp. 14-14(1)

Empirical methotrexate not ideal for suspected ectopic pregnancy
pp. 14-14(1)

Long-term exercise programme not justified economically in RA
pp. 15-15(1)

Mammography: better outcomes, lower costs than self-examination
pp. 15-15(1)

Office visits, prescribing rate for vulvovaginal candidiasis declining
pp. 15-15(1)

Mifepristone + misoprostol good cost option for medical abortion
pp. 15-15(1)

Clarithromycin, amoxicillin/clavulanic acid in acute sinusitis
pp. 16-16(1)

Tipranavir at least as effective as comparators in AIDS
pp. 16-16(1)

QOL, survival gains with new cancer treatment option
pp. 16-16(1)

Adalimumab in it for the long haul in psoriasis
pp. 17-17(1)

Visuospatial cognition, mood and QOL are not significantly improved in elderly men following treatment with testosterone undecanoate
pp. 17-17(1)

Spanish price cut decree goes to court
pp. 18-18(1)

A period of radical change is forecast for the global cardiovascular drug market, due largely to the loss of patent protection for current blockbusters
pp. 18-18(1)

Drug sales up, advertising to be banned in China
pp. 18-18(1)

Healthcare, drug development funding news
pp. 18-18(1)

Gilead Sciences, Inc. has announced the expansion of its global Access Program for HIV medicines to include additional countries in the Caribbean and Latin America.
pp. 18-18(1)

Generic drug sales continue to flourish in France, assisted by a favourable regulatory regime and a surge of patent expiries for leading drugs
pp. 19-19(1)

New Zealanders can now purchase the weight loss drug orlistat [Xenical; Roche] over the counter (OTC) without a prescription
pp. 19-19(1)